2022: Genentech re-launches Susvimo eye implant in US after 2021 recall for performance issues.
Roche's Genentech unit has re-launched its eye implant Susvimo in the US, after voluntarily recalling it last year due to some implants not meeting performance standards. The device was approved in 2021 to treat wet age-related macular degeneration and will be available to US patients in the coming weeks. Genentech has since updated the implants and testing confirmed they now meet performance standards.
July 08, 2024
7 Articles